Research summary, original research, 2015

Long-Term Strategies Support Autonomy In Radiation Safety In Invasive Cardiology

Kuon E, Felix SB, Weitmann K, Büchner I, Empen K. Journal of cardiology. 2015

Read the original paper

In plain language

Over 15 years, one experienced interventional cardiologist cut median patient dose for coronary angiography from 33.8 to under 1 Gycm2 using collimation, low pulse rates, ECG-gated frames and training. Staff dose was not measured, though such methods usually lower it too.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Interventional cardiologists, Patients
Where
Germany
Summary based on
the abstract

What it found

  • Median patient dose area product for coronary angiography fell sharply over 1997 to 2012 with iterative radiation-reducing strategies by one experienced interventionalist.

    Key figures: 33.8 Gycm2 baseline to 2.4 Gycm2 (conventional) and 0.6 Gycm2 (ECG-gated)

  • Median patient effective dose dropped to submillisievert levels.

    Key figures: 6.76 mSv to 0.48/0.13 mSv (C/E mode)

  • Number of radiographic frames per procedure fell markedly, especially with ECG-gated acquisition.

    Key figures: 548 to 105/25 frames

  • Fluoroscopic dose rate per second fell about tenfold, while fluoroscopy time decreased less.

    Key figures: Dose-area product (DAP)(F)/s 48.9 to 4.4/3.1 mGycm2/s; fluoroscopy time 195 to 120/119 s

  • Final values are far below the 2013 German Registry median DAP for coronary angiography.

    Key figures: 19.8 Gycm2 registry median

Limits to keep in mind

Single experienced operator at one centre with representative cohorts of unstated size; only patient dose metrics were measured, not staff dose, and changes over 15 years may reflect equipment upgrades as well as technique.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.